Vistagen Plans FDA Meeting on Fasedienol After Mixed Phase 3 Data
VTGN sits 38% above its 52-week low of $0.198 on light trading volume (0.1× avg).
Summary
Vistagen reported fiscal Q1 2027 results and outlined next steps for fasedienol after the PALISADE-4 miss. The company plans to meet with the FDA this quarter to discuss a potential Phase 3 path forward, citing post-hoc efficacy in very severe social anxiety patients. New data from the PALISADE-3 open-label extension and a Phase 2 repeat-dose study also showed numerical separation from placebo in that subgroup. Cash preservation and cost management remain priorities as the company works to extend its runway. The appointment of Dr. Douglas Williamson to the board adds neuroscience expertise ahead of regulatory discussions. Q1 revenue rose on a licensing agreement expiration.
At the time of this announcement, VTGN was trading at $0.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.8M. The 52-week trading range was $0.20 to $5.14. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.